Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis

Who May Qualify: - Patients aged 18- 70 years of either gender. - Only patients with Psoriasis Area and Severity Index (PASI) score of 10 or above, and/or Body Surface Area (BSA) involvement of 10% or more, will be included. - Duration of plaque psoriasis for at least 6 months prior to the study. - Psoriasis that has not shown adequate response to topical therapies Who Should NOT Join This Trial: - Individuals with other forms of psoriasis or other significant dermatological conditions that might interfere with the assessment of psoriasis. - Participants currently receiving systemic corticosteroids, biologics, or any other immunosuppressive agents within 4 weeks prior to the start of the study will be excluded. - Known hypersensitivity or contraindications to either methotrexate or tofacitinib. - History of significant liver, kidney, hematologic/bleeding disorder, gastrointestinal/acid peptic disease, or immune system disorders.and any history of tuberculosis and malignancy. - Pregnant or lactating women will not be eligible for the study. Always talk to your doctor about whether this trial is right for you.